surpass tirzepatide SURPASS-CVOT: Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D ๐ก New insight in diabetes
Pay in 4 interest-free payments of $6.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6
Live Spec
New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What SURPASS to SURMOUNT: The Tirzepatide Trials To Know Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis YouTube Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS 4): a randomised, open label, parallel group, multicentre, phase 3 trial The Lancet Once weekly tirzepatide versus once daily insulin degludec as add on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS 3): a randomised, open label, parallel group, phase 3 trial The Lancet
Store: psychwardcomics.com ยท Domain: psychwardcomics.com


02188-7/asset/1f15c5ee-e9c1-4058-8e74-d7dafaec62ef/main.assets/gr2.jpg)
01443-4/asset/1245bc8d-99c6-4ac1-b69b-8c0220ceb8fd/main.assets/gr1.jpg)



















